BIOBOT Surgical

Executive Summary

BIOBOT Surgical is a Singapore-based medtech company commercializing the Mona Lisa robotic transperineal platform for prostate cancer diagnosis and treatment. The system integrates a robotic arm with MRI-ultrasound fusion to enable precise needle placement for biopsies and soft-tissue ablation, achieving improved cancer detection rates while reducing infection risk compared to traditional transrectal approaches. Since its founding in 2015, the company has progressed to commercial stage, targeting the growing global prostate cancer diagnostic market. With its focus on accuracy and patient safety, BIOBOT Surgical is well-positioned to capture share in the shift toward minimally invasive, robot-assisted procedures. The platform's differentiated technology addresses significant unmet needs in prostate cancer management, including higher detection rates for clinically significant cancer and lower complications.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for Mona Lisa system60% success
• Q3 2026Publication of prospective clinical study results demonstrating superiority over standard biopsy50% success
• Q2 2026Strategic partnership or distribution agreement in Asia-Pacific region70% success